Merck & Co Inc (MRK)

MRK on New York Consolidated

56.47USD
17 Apr 2014
Price Change (% chg)

$0.21 (+0.37%)
Prev Close
$56.26
Open
$56.45
Day's High
$57.00
Day's Low
$56.27
Volume
11,263,310
Avg. Vol
12,595,437
52-wk High
$58.14
52-wk Low
$44.60

MRK

Chart for MRK

About

Merck & Co., Inc. (Merck) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company consists of four operating segments, which are the Pharmaceuti... (more)

Overall

Beta: 0.48
Market Cap (Mil.): $165,439.41
Shares Outstanding (Mil.): 2,940.62
Dividend: 0.44
Yield (%): 3.13

Financials

  MRK Industry Sector
P/E (TTM): 38.12 32.99 33.14
EPS (TTM): 1.48 -- --
ROI: 5.30 19.69 18.95
ROE: 8.57 20.38 19.71
Search Stocks

Merck's ragweed pollen allergy drug gets U.S. approval

- The U.S. Food and Drug Administration has approved Merck & Co's pollen allergy drug Ragwitek.

3:58pm EDT

CORRECTED-Merck's ragweed pollen allergy drug gets U.S. approval

(Corrects fourth paragraph to say Grastek, not Ragwitek, will compete with Stallergenes' drug)

3:57pm EDT

Merck's grass pollen allergy drug wins U.S. approval

- Merck & Co said the U.S. Food and Drug Administration on Monday approved its grass pollen allergy drug Grastek, becoming the second such immunotherapy treatment to be given the go-ahead in recent weeks.

14 Apr 2014

UPDATE 1-Merck's grass pollen allergy drug wins U.S. approval

April 14 - Merck & Co said the U.S. Food and Drug Administration on Monday approved its grass pollen allergy drug Grastek, becoming the second such immunotherapy treatment to be given the go-ahead in recent weeks.

14 Apr 2014

Merck's grass pollen allergy vaccine wins U.S. approval

April 14 - Merck & Co Inc said the U.S. Food and Drug Administration on Monday approved its grass pollen allergy vaccine, Grastek, for patients aged 5 to 65.

14 Apr 2014

Merck hepatitis C drugs shine in easier to treat patients: study

- A two-drug combination being tested by Merck & Co to treat hepatitis C cured 98 percent of previously untreated patients without cirrhosis in a midstage clinical trial, providing the latest evidence that the U.S. drugmaker will be highly competitive in the fast evolving field.

10 Apr 2014

Merck hepatitis C drugs shine in easier to treat patients -study

April 10 - A two-drug combination being tested by Merck & Co to treat hepatitis C cured 98 percent of previously untreated patients without cirrhosis in a midstage clinical trial, providing the latest evidence that the U.S. drugmaker will be highly competitive in the fast evolving field.

10 Apr 2014

Untaxed U.S. corporate profits held overseas top $2.1 trln -study

* Senate Finance Committee Chairman Wyden calls for reform

08 Apr 2014

Exclusive: Merck wants to test Zilmax on 240,000 cattle but beef industry resists

CHICAGO - Merck & Co Inc wants to feed its controversial feed additive Zilmax to 240,000 U.S. cattle to prove it is safe. But there is a problem: giant meat processors like Cargill Inc don't want to touch animals fed with the drug.

04 Apr 2014

UPDATE 1-Stallergenes wins U.S. go-ahead for Oralair allergy pill

* Merck and partner ALK Abello expected to launch rival drug this year

02 Apr 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks